An estimated 126,700 people in Washington over age 65 have Alzheimer's, according to estimates released by the Alzheimer's Association in 2023.
Alzheimer's disease afflicts an estimated 6.7 million Americans, and that number is only growing. Medical professionals believe the volume of diagnoses could double by 2060 if there isn't a breakthrough in prevention—or a cure.
For the first time, the Alzheimer's Association released estimates on Alzheimer's prevalence in each state and county. Researchers hope these figures will help regional public health officials better treat Alzheimer's patients, develop localized care plans, and budget for care—particularly as new treatments come at a cost.
Alzheimer's is the most common form of dementia and is among the top 10 causes of death in the U.S. These deaths are increasing as fatality rates from other health-related causes, including heart disease and stroke, are on the decline. With Alzheimer's, the brain shrinks, brain cells die, and peoples' memory and language centers fail. As the disease advances, the loss of brain function leads to dehydration, malnutrition, infection, and ultimately death.
Developing a cure or effective treatment has been slow, as medical professionals still don't know what causes Alzheimer's. But earlier this year, the Food and Drug Administration fully greenlit the first drug proven to effectively treat the disease: lecanemab (sold under the brand name Leqembi), created by Eisai Inc. and Biogen. Earlier treatments only addressed symptoms of Alzheimer's, while lecanemab treats the early stages of the disease itself and slows its progression.
The drug costs $26,500 annually and is partially covered by Medicare if a patient's medical team participates in a registry to track the drug's outcomes. Those high costs could keep the treatment out of reach for low-income Americans, who already have higher odds of developing Alzheimer's, studies have shown.
Nearly all Alzheimer's patients are on government insurance, and estimates show that Medicare could spend $2 billion to $5 billion annually on lecanemab and related care. That pales in comparison to the $345 billion that Alzheimer's and other dementias cost in 2023, including nursing home stays, symptom management medications, and other care for those with the disease. Without medical advancements, the Alzheimer's Association expects those costs could rise to nearly $1 trillion by 2050.
If lecanemab and similar drugs can slow progression in even half of mild Alzheimer's patients, one study from the University of Chicago estimates Americans would save $212 billion to over $1 trillion in care-related costs over the next decade.
Having a treatment to slow the progression of Alzheimer's also creates more urgency to diagnose the disease sooner to retain more brain function. Warning signs for the disease include disruptive memory loss, difficulty with familiar tasks, worsening judgment, and changes in mood and personality.
The U.S. has a shortage of specialists in elder and memory-related medicine and nurses providing care at nursing homes and assisted-living facilities. In regions with high rates of Alzheimer's, these shortages could be catastrophic within the current models of care.
Stacker mapped states by the share of the population over age 65 that is estimated to have Alzheimer's disease, using data released by the Alzheimer's Association in July 2023. As a part of the national analysis, Stacker also took a closer look at Washington and ranked the counties within it by their estimated Alzheimer's prevalence.
